Greece plans to use floating barrier to block migrants from reaching islands – Daily Sabah

Greece is planning to use a floating barrier to stop migrants from reaching the Greek islands from the nearby coast of Turkey.

The Defense Ministry has invited private contractors to bid on supplying a 2.7-kilometer-long floating fence within three months, according to information available on a government procurement website Wednesday. No details were given on when the barrier might be installed.

A resurgence in the number of migrants and refugees arriving by sea to Lesbos and other eastern Greek islands has caused severe overcrowding at refugee camps.

The netted barrier would rise 50 centimeters above water and be designed to hold flashing lights, the submission said. The Defense Ministry estimates the project will cost 500,000 euros ($550,000), which includes four years of maintenance.

Greece's six-month-old center-right government has promised to take a tougher line on the migration crisis and plans to set up detention facilities for migrants denied asylum and to speed up deportations back to Turkey.

Nearly 60,000 migrants and refugees made the crossing to the islands last year, nearly double the number recorded in 2018, according to data from the United Nations' refugee agency.

To reduce the number of illegal migrants on the dangerous Aegean Sea route, Turkey and the European Union signed an agreement in 2016. The deal stipulates that Greece is to send migrants held on its Aegean islands back to Turkey. In return, Turkey is to send Syrian migrants it hosts to various European Union countries.

According to the deal, Turkey was promised a total of 6 billion euros in financial aid, which was initially designed to be given to the country in two stages and be used by the Turkish government to finance projects for Syrian refugees. Visa freedom for Turkish citizens was also to be provided under the agreement. Lastly, the customs union was also to be updated in accordance with the deal.

In exchange for these promises, Turkey took the responsibility of discouraging irregular migration through the Aegean Sea by taking stricter measures against human traffickers and improving the conditions of more than 3 million Syrians living in Turkey.

Despite significant developments in the control of migration traffic, the EU has not delivered on its commitments.

Turkey and Greece have been key transit points for irregular migrants aiming to cross to Europe to start new lives, especially those fleeing war and persecution.

Adalbert Jahnz, a spokesman for the European Commission, on Thursday warned that any planned Greek sea barriers to deter migrants must not block access for asylum seekers while noting that the EU executive has not seen the proposals.

"The installation of barriers is not in of itself contrary to EU law," the commission spokesman said. "Such types of barrier or physical obstacles must not make access to the asylum procedure impossible for those who may potentially need it."

EU member states must also respect the principle of non-refoulment, under which asylum seekers must not be sent back to a country where they would be in danger of persecution, Jahnz noted, adding that any measures must be proportional.

The commission will be in contact with Athens to get more details on the proposal and its aims, the spokesman added.

Excerpt from:

Greece plans to use floating barrier to block migrants from reaching islands - Daily Sabah

‘Britain is retrenched on its island’: Europe’s papers react to Brexit day – The Guardian

Europes media greeted the bright new post-Brexit dawn of Britains first day as an ex-member of the European Union with some sadness, a healthy dose of scepticism, and a plea to the the bloc to get its act together.

The end, wrote Frances Libration. Britain has left the EU and theres not much else to say. After 47 years at the heart of a unique club of nations, after three years and seven months of drama, plot twists and chaos, it is out, retrenched on its island, alone.

The end was a bit of a damp squib, the paper said. Most people did nothing, seeking a normal Friday evening without too many questions about what comes next. Brexit and its consequences have only just begun. Tomorrow is another day, Brexited.

Le Monde said 31 January was the day nothing changed, and everything changed. The Parliament Square crowd vanished minutes after singing God Save the Queen, with no hanging around in keeping with a strange day when Britain celebrated a truly historic event, but only barely. Can one really celebrate a divorce?

It was as if everyone somehow sensed that the farewell formalities that moment when you find yourself on the pavement, at once relieved and saddened, before everyone heads their separate ways had to be kept as brief as possible.

In Germanys Sddeutsche Zeitung, Stefan Kornelius warned that no country was an island, not even Britain. Sovereignty is a popular term in an era crying out for order and security, he wrote. But it assumes you are the master of your destiny that you can ward off unreasonable demands from the outside world.

This was a nice idea in a world that has created huge dependencies, Kornelius said. The song is of an end to vassalage and humiliation, but Britain has no great ideas for the future so far, all we have seen been a narrow-minded denial of reality and a trivialisation of the problems.

Die Welt warned of the consequences of Brexit-fuelled delusions of grandeur, saying much would depend on whether British politics, after Brexit, can finally be honest about the countrys true size. It quoted the prophetic words of a government scientific adviser, Henry Tizard, in 1949.

We persist in regarding ourselves as a great power, capable of everything and only temporarily handicapped by economic difficulties, Tizard wrote, in a memo instantly filed away. We are not a great power and never will be again. We are a great nation, but if we continue to behave like a great power we shall soon cease to be a great nation.

Spains El Pas said Boris Johnson now faced a challenge of colossal dimensions: to recover the unity of a country divided between those who see Brexit as a liberation, and those who consider it a tragedy and a historical error.

He will also need to finally define Brexit, and in doing so risks, despite his large majority, reigniting another old war: that between free trade fans, who aspire to break completely with the EUs rules, and those who in the coming months will start to see the consequences of Brexit for farmers, fishermen and businesses.

In the Netherlands, Caroline de Gruyter warned that the EU needed to get moving. Until now, Brexit has been good for the EU, she wrote in NRC Handelsblad. Polls, she said, show public appreciation of the EU and the euro at their highest levels ever.

The 27 are united. That earns admiration from citizens. Europeans were shocked to see the UK sink into political chaos, and to hear talk of food and medicine shortages under a no-deal Brexit; they concluded it is better to stay together. You no longer hear populists like Marine Le Pen and Geert Wilders talk about Frexit or Nexit.

But it would be naive to assume things will stay that way, De Gruyter said. Just as the EU benefits from a disastrous Brexit, a successful Brexit can undermine the EU as the former Italian prime minister Matteo Renzi said the EU project must be given a new impetus. Brussels must start moving: ideas, dreams, soul. Its time.

Read this article:

'Britain is retrenched on its island': Europe's papers react to Brexit day - The Guardian

Two men found dead, third still missing as search continues on Vancouver Island – Vancouver Sun

Corey Mills, Eric Blackmore and A.J. Jensen have been missing since Friday night. They are likely off-road near Sooke.Facebook

Theres been a tragic end to a weekend search for three young men on southern Vancouver Island.

RCMP Staff Sgt. Janelle Shoihet says the vehicle the three men were in was found near Sooke River Road on Sunday and the bodies of two of the men have been recovered.

She says RCMP and Juan de Fuca Search and Rescue are searching for the third man.

Police said in an earlier news release that Cory Mills, Eric Blackmore and AJ Jensen, all 20 years old, were last seen at a home in Sooke late Friday night.

The men were in a 2004 blue Dodge Dakota and it was unclear where they going.

Victoria Weber of Juan de Fuca Search and Rescue says hundreds of people turned out to help in the search on Sunday, assisted by a helicopter, ATVs and boats scouring the shoreline. The volunteers were asked to stabnd down once the missing truck was spotted from a helicopter.

Shoihet says the B.C. Coroners Service is also investigating to determine how, when and by what means the men came to their deaths.

Go here to read the rest:

Two men found dead, third still missing as search continues on Vancouver Island - Vancouver Sun

David Ross: Digging for answers to island’s problems – Press and Journal

Last month, at a special ceremony, the Right Hon Lord Reed of Allermuir was installed as president of the Supreme Court.

He is the first Scottish judge to reach this professional pinnacle.

At the London base of the UKs highest tribunal, on Parliament Square, details of his outstanding legal career and acclaimed scholarship, were recalled.

There was, however, no mention of Leverburgh Village Hall in the south of Harris. This was the setting for one of the most difficult professional positions in which Lord Reed had ever found himself.

Between October 1994 and June 1995, he represented the Western Isles Council at the public inquiry into the proposed superquarry at Lingerbay on Harris. It would have meant the removal of a good part of the mountain, Roineabhal, to create the largest superquarry in Europe, which would have been clearly visible from space.

There were islanders who, along with many conservationists, always viewed it as an environmental outrage.

But initially many locals saw Redland Aggregates 70m project, to extract 600 million tonnes of the mineral anorthosite from the mountain for road-building, as a chance to reverse decades of chronic depopulation.

Harris had been losing its people for generations, and was still doing so. Between 1951 and 1991, the figure (including Scalpay) fell by almost 40%.

A referendum in 1993 found 62.1 % of the islanders supported the project.

The council duly gave consent for the development. In October that year the then-Secretary of State Ian Lang announced a planning inquiry. It was to be the longest in Scottish planning history, sitting for 100 days, with over 100 witnesses, and considered almost 500 written representations.

But the night before the inquiry ended, the islands council performed a complete volte-face.

In May 1995 the Harris Council of Social Service commissioned the Electoral Reform Society to conduct a second poll, which attracted an 82.7 % response, with 67.7% now opposing the development

The council reversed its position, voting by 21 votes to eight to oppose the superquarry.

This left Dr Reed in an impossible position, having spent the previous eight months arguing for the development.

As it was, reporter Gillian Pain closed the inquiry. But if Lord Reed ever writes his autobiography, the chapter on this episode will make interesting reading.

Miss Pain then took four years to complete her report and retired from her job, finishing it as a paid consultant of the Scottish Office. In May 1999, the inquiry report was delivered to the then Labour/Lib Dem Scottish Executive, but took until March 2000 before it finally arrived on the environment ministers desk.

Four months later, the minister, Sarah Boyack, told the Scottish Parliament that before making a decision, she had decided to refer to SNH the question of whether any part of the quarry site should be proposed as a candidate for a Special Area of Conservation.

Enough was enough, and developers Redland Aggregates went to the Court of Session, where Lord Hardie described the near-10-year delay in producing a decision on the superquarry as a failure of scandalous proportions. He said the minister had not only exceeded her powers but acted irrationally when she decided to ask SNH to get involved.

By November 2000 Sarah Boyack had been replaced by the late Sam Galbraith, who almost immediately rejected the planning application. The former neurosurgeon told friends: When you are guddling about in peoples brains, youve no option but to take decisions quickly and move on.

This came nine and a half years after the planning application was first lodged.

Gillian Pain actually concluded that the 200 direct and indirect jobs created by the quarry would have been worth the undoubted environmental damage to Harris.

It was an exhausting episode for the islanders. Many mainland-based opponents of the quarry had predicted a healthy green future for Harris through alternative developments. But they seemed to disappear back into the woodwork.

Harriss population continued to decline, dropping by nearly 14% between 1991 and 2011. There has been a small revival in West Harris, but a 13.7% decrease by 2039 has been forecast for all the Western Isles. Most worrying is that it is the under-15 age group which is predicted to fare worst, with a drop of 28%.

The signs are already here. It has just been reported that the number of babies registered in the Outer Hebrides reached a new low of 200 last year, more than 100 down in just 25 years, despite a rise reported earlier in the Uists.

It should be remembered, this demographic gloom comes at a time when tourism in Harris and the other islands has been booming.

That looks set to continue with the Outer Hebrides named as one of the top 19 destinations in the world to visit last year.

Removing a mountain was obviously a pretty drastic idea. There must be another way. Increasing visit numbers alone is not the answer. It is going to take more than motorhomes and Airbnb listings to finally reverse population decline in islands like Harris.

David Ross is a veteran Highland journalist and author of an acclaimed book about his three decades of reporting on the region

Go here to read the rest:

David Ross: Digging for answers to island's problems - Press and Journal

Staten Island man busted in Florida; charged with stealing items from a boutique – SILive.com

STATEN ISLAND, N.Y. -- A Staten Island man was arrested in Palm Beach, Florida, on Friday, charged with shoplifting multiple items from a boutique store, according to the Palm Beach Police Department.

Janos Buda, 49, of the 100 block of Sliver Lake Road in Brighton Heights, allegedly tried to steal merchandise from the Neiman Marcus store in Palm Beach, according to the criminal complaint.

Security personnel saw Buda in the surveillance cameras walk around the fragrance department at the store, pick up a mens fragrance tester and put it in a shopping bag he had with him, the complaint indicates.

Buda also took a sealed box of Tom Ford perfume and put in the shopping bag, according to the complaint.

At that point the store security confronted Buda and found multiple items in the bag that were from the store, including denim jeans, denim slacks, a formal shirt, a Tom Ford bottle of perfume and a Tom Ford tester, the criminal complaint details.

The total worth of the items was $2,214, police said in the complaint.

I am sorry, Buda allegedly said after officers from the Palm Beach Police Department showed up at the store, according to the complaint.

After the officers read Buda his Miranda rights, the Brighton Heights man said he was very sorry for taking the items and asked a Neiman Marcus employee if he could pay for the items, the complaint indicates.

Buda said he had the money in his wallet, but then said that he wasnt going to pay for them, according to the complaint.

Buda was released the next day after posting a $5,000 bond, according to public records.

Public records do not indicate a publicly available lawyer for Buda.

Read the original here:

Staten Island man busted in Florida; charged with stealing items from a boutique - SILive.com

Precision Medicine Leaps Ahead with Data Science: Bio-IT World 2020 to Highlight Data-Driven Approaches to Discovery – BioSpace

More than 3,200 such experts from pharmaceutical, biotech, healthcare and technology organizations, government and academia will converge for the 19th annual event, taking place April 21-23, 2020 in Boston.

Data science is foundational to life science companieschanging the competencies required to compete. The opportunities to push our industry to the edge of discovery are thrilling for those organizations that embrace a collaborative, data-driven approach, said Allison Proffitt, Editorial Director, Bio-IT World.

From a plenary keynote presentation on the National Institutes of Healths (NIH) Strategic Vision for Data Science, to a new Data Science and Analytics Technologies track with Bristol-Myers Squibb, Takeda and more, the conference will highlight effective strategies, analytics and tools.

Altogether, 16 conference tracks will cover AI for Drug Discovery, Bioinformatics, Data Storage and Transport, Pharmaceutical R&D Informatics, Cancer Informatics, Genome Informatics, Clinical Research and Translational Informatics, Data and Metadata Management, Data Visualization Tools, Emerging AI Technologies, AI: Business Value Outcomes, Software Applications and Services, Data Security and Compliance, Cloud Computing, and Open Access and Collaborations, in addition to Data Science and Analytics Technologies.

Other highlights include 250+ presentations, 160+ exhibitors, Plenary Keynotes, pre-conference workshops, a Hackathon, awards, poster sessions and networking. See details at bio-itworldexpo.com.

About Cambridge Healthtech Institute Cambridge Healthtech Institute (CHI), a division of Cambridge Innovation Institute, is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech, CROs, academia, and niche service providers. CHI is renowned for its vast conference portfolio held worldwide including PepTalk, Molecular Medicine Tri-Conference, SCOPE Summit, Bio-IT World Conference & Expo, PEGS Summit, Drug Discovery Chemistry, Biomarker World Congress, World Pharma Week, The Bioprocessing Summit, Next Generation Dx Summit, Immuno-Oncology Summit, and Discovery on Target. CHI's portfolio of products include Cambridge Healthtech Institute Conferences, Barnett International, Insight Pharma Reports, Bio-IT World, Clinical Research News and Diagnostics World.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200128005512/en/

Follow this link:

Precision Medicine Leaps Ahead with Data Science: Bio-IT World 2020 to Highlight Data-Driven Approaches to Discovery - BioSpace

Understanding this rare disease could help treat aspects of aging – Ottawa Citizen

Young Indian progeria sufferer Rupesh (C) sits with his mother Shanti Devi (L) and younger brother Vakil (R) at Allahabad District Magistrates Office in Allahabad on May 2, 2017, as they seek government financial support for his treatment. 21 year old Rupesh who comes from a village on the outskirts of Allahabad suffers from progeria disease, also known as Hutchinson-Gilford progeria syndrome (HGPS), which causes premature aging as a result of a genetic condition it affects some 1 in every 4 million births across the world.SANJAY KANOJIA / AFP via Getty Images

Progeria, also known as Hutchinson-Gilford Progeria syndrome, is a very rare disease, representing about one in six million births.

Progeria is aging on steroids. Babies with the syndrome are born without complications, but within a year or two, theyre not growing normally. They lose their hair and develop wrinkles. Most patients die before they leave their teens of heart attacks or stroke.

It would appear that understanding progeria and figuring out how to slow down the clock for progeria patients could be a key to treating aging itself. But while progeria has offered researchers a number of insights, the parallels between progeria and aging are not exact, said William Stanford, a senior scientist in regenerative medicine at the Ottawa Hospital Research Institute and a professor of cellular and molecular medicine at the University of Ottawa.

For example, plaque build-ups in the arteries of progeria patients in their teens look like those of a heart patient in their 90s. Progeria patients produce an abnormal form of a structural protein expressed in all cells. This abnormal protein known as progerin is also found in almost everyone in their 70s and 80s.

There are other differences between progeria patients and aging people. People with progeria dont show the same kidney and liver decline as older people, for example.

Research by Stanford and his colleagues has found it is possible to reprogram the progeria cells and essentially reset the clock. However, while this works in a culture dish, it has not progressed to animal studies, let alone human trials. A drug can slow down the process of aging on a cellular level, but it corrects only some of the cellular defects, not all.

The way I see it, theres a whole laundry list of things that go wrong with aging, said Stanford.

In the past decade, a cocktail of three different drugs that reduces Progerin accumulation combined with better medical care has helped extend the lives of progeria patients by at least two years. But treating ordinary people with the same drugs wont extend their lives.

Some of the insights gained by studying progeria may have benefits for treating heart disease in the general population, and thats a good thing, considering that heart disease is one the top causes of death in Canada, said Standford. But that knowledge may not extend to treating other age-related illnesses.

Read the original here:

Understanding this rare disease could help treat aspects of aging - Ottawa Citizen

There could be a link between marijuana use and heart health – Medical News Today

New research found that 2.3% of reported marijuana users also have some form of cardiovascular disease.

The study appeared in the Journal of the American College of Cardiology.

The paper also looked at the possible interactions marijuana may have with drugs typically prescribed for cardiovascular issues, and the way marijuana chemicals may affect the heart at a molecular level.

According to the Centres for Disease Control and Prevention (CDC), heart disease a type of cardiovascular disease (CVD) is the leading cause of death in the United States.

In 2015, heart disease caused 23.4 % of all deaths in the U.S.

According to the American Heart Association (AHA), nearly half of all U.S. adults have some form of CVD. They cite an article in the journal Circulation that sets this figure at 121.5 million U.S. adults, which is approximately 48% of the population.

In contrast, the reported 2.3% of reported marijuana users who also have CVD is relatively low compared to the broader U.S. population.

This does not mean that marijuana use and CVD have no links. However, there is insufficient evidence to prove any connection, and what is available is of poor quality.

In the U.S., there are significant restrictions on researching marijuana. This means that scientists cannot carry out randomized clinical trials to understand its effects on health.

Researchers typically focus their research on observational studies, and the authors of the study claim that these show a possible link between marijuana use and cardiovascular events.

However, according to an article in the journal Annals of Internal Medicine, observational studies that have taken place are either inconclusive or have problems with their methodologies. This means that it is difficult for scientists to draw any conclusions from them.

The authors of the article in the Journal of the American College of Cardiology looked at data from the National Health and Nutrition Examination Survey (NHANES) to estimate how many marijuana users have CVD.

They found that 2 million of the 89.6 million U.S. adults who reported using marijuana also had CVD. This equates to 2.3% of reported marijuana users.

Dr. Ersilia M. DeFilippis, a former internal medicine resident at Brigham and Womens Hospital, Boston, MA, is the lead author. She is now a cardiology fellow at Columbia University Irving Medical Center.

She says, Marijuana use, both recreational and medical, is increasing nationally, yet many of its cardiovascular effects remain poorly understood. In our NHANES query, we estimated that 2 million adults with marijuana use had CVD in 20152016.

Since that time, additional states have passed legislature related to marijuana, so its use may have increased even further.

Notably, many of our cardiology patients are on medications that can interact with marijuana in unpredictable ways, depending on the formulation. This highlights that we need more data so that we can better counsel providers as well as patients.

Given the increase in marijuana use in the U.S., the authors of the study urge doctors to ask patients whether they use marijuana and to review their medication if necessary.

Current evidence is limited, and what little there is does not suggest a clear link between marijuana use and cardiovascular events. Researchers need to do more high quality research to determine precisely how and why marijuana affects cardiovascular health if it does at all.

According to the corresponding author Dr. Muthiah Vaduganathan, who is a cardiologist at Brigham, In the clinic, patients often ask us about the safety of marijuana use, and were pressed to offer the best scientific evidence.

Our current approach is that patients who are at high risk of cardiovascular events should be counseled to avoid or at least minimize marijuana use and that rigorous scientific research should be conducted to further inform recommendations for patient care.

Dr. Muthiah Vaduganathan

Before this can happen, however, authorities will need to lift the restrictions on marijuana research.

Read the original:

There could be a link between marijuana use and heart health - Medical News Today

Urgent Care, Telemedicine – Ways Going to the Doctor Is Changing – Men’s Health

Any doctor will tell you that every guy needs a primary-care providera trusted physician who knows you, knows that your dad had a heart attack at age 40, helps you figure out how to tweak your life according to your health historyand heck, knows your name without looking at your chart first.

Except that for most of us, thats not how it goes. First, the doctor never sees us, because the yearly visit has been called off. Theres no reason for healthy men under 40, or anyone for that matter, to get annual checkups, says Eric Topol, M.D., a professor of molecular medicine at Scripps Research in La Jolla, California, echoing the view of the Society of General Internal Medicine. Having an annual exam does not reduce your risk of death or serious disease, according to a review of 14 studies. When it comes to yearly checkups, all the data shows the lack of value, and they should be strongly discouraged, Dr. Topol says.

Second, we move around. If you take a 21-year-old male in 2020 and ask, Where are you going to get care today versus five, ten, or 20 years from now? hes not going to know, because people change employers, health plans, and even doctors relatively frequently, says Ateev Mehrotra, M.D., an associate professor of public health-care policy and medicine at Harvard Medical School. So the question is: Is that relationship even possible?

Add to that issues with cost and convenience and its no wonder nearly half of adults in the U.S. under age 30 dont have a primary-care physician.

Andtwist you didnt see coming!maybe thats okay.

There are now many cheaper, more convenient ways to get medical help than waiting for a traditional doctors office to fit you in and potentially having to travel to get there. And if youre basically healthy, you might do fine with these.

Subscribe Now

MensHealth.com

But with choice and convenience comes great responsibility. Most millennials use urgent care, go online, talk to their friends, and think thats health care, says Allan H. Gorroll, M.D., a professor of medicine at Harvard Medical School. Its not. A catch-as-catch-can health plan leads to a lot of issues not getting caught. With this approach, some things may be overlooked or prescribed inappropriately, he says.

So youve got to have a plan. Not all of these answers to medical-system frustration are equal. Some are welcome, some dodgy, some outright dangerous, and some ingenious.

Look, if you have a doctor you love, stick with them. And if you have a chronic illness like diabetes or high blood sugar thats about to turn into diabetes, or if youre at high risk for anything else (like heart disease), then yes, youre going to need a main doctor.

But today, the old way is only one way to get what you need. If youre going to bypass a PCP, then let us show you how to navigate whats out there so that you find the best route to the best care.

Heres the lowdown on which new ways to see the doctor spare you time, money, and scheduling hassles without endangering your health.

You get to talk to or videoconference with a real doctor without making an appointment or even leaving your living room/car/office/campsite. Some big insurance companies have partnered with big telehealth start-ups, including Teladoc, Doctor On Demand, and American Well, so these options may be part of your plan. In 2018, an estimated 7 million people visited a doc this way.

You can find and use a telehealth site or app yourself, but youll have to do some homework on your choices before dialing.

The pros: Speed. Ease. Since youre calling or video chatting about a specific problem, such as a sore throat, youll likely be spared the you need to lose weight speech. And research has shown that people may be more honest in revealing symptoms or undesirable behaviors like alcohol consumption when disclosing to a computer.

The cons: Not all telehealth providers are equalsome have been scammy. So when choosing an app, look for one partnered with a known health-care entity, like Blue Cross Blue Shield or a hospital that you trust. Then see who the doctors aresome apps list providers names and contact information, so you can check them out online.

Science Photo LibraryGetty Images

More than half of all millennials seek help from urgent care (like Concentra, CityMD, and MedExpress) or retail health clinics, found in drugstores, supermarkets, or big box stores. Retail clinics are typically manned by a nurse practitioner or physicians assistant; theyre good at managing minor scrapes, colds, and fevers, and they can give you a flu shot. But they cant X-ray you or stitch you up. Freestanding urgent-care centers are for pressing but non-life-threatening medical issues (so bypass them for an ER if you have chest pain) and are generally staffed by a licensed physician.

The pros: Theyre cheaper and faster than the ER, they can usually send a report to you to keep on file (and to a doctor, if you have one), and theyre everywhere.

The cons: They may overprescribe meds. One recent study discovered that nearly half of people who dropped into urgent care with an ear infection, flu, allergies, asthma, bronchitis, or another viral upper-respiratory infectionnone of which respond to antibioticsgot a prescription. Retail clinics had the best track recordantibiotics were inappropriately prescribed only 14 percent of the time there (and 17 percent of the time at a doctors office).

If you need a prescription for an issue like ED, genital herpes, performance anxiety, or hair loss, a few finger taps can get you one from a digital health clinic such as Hims.

The pros: No embarrassing in-person doctor visit needed. Fill out an online formyoull answer a lot of questions about your issue and your health history (youve got to be honest)to determine if youre eligible for the prescription youre after. If a doc has questions or concerns, they may call you. Your medication arrives at your door a few days later.

The cons: The idea of getting meds with little human contact ruffles the feathers of practically every careful human prescriber we know. But it might not be as sketchy as all that: Dr. Mehrotra sent college students undercover to test online prescription apps and sites. My initial skepticism was tempered, he says. Thats still not a ringing endorsement, by the way.

These fancy doctors offices/wellness centers are about as far as you can get from low-contact telehealth apps. Packages vary by company, but monthly fees can get you a round of initial diagnostics and a certain number of appointments with those physicians every year. The promise is that these docs have extra time to spend with you not only to solve your health problem but also to help determine lifestyle changes to keep it in check and prevent other issues. At a company called Forward, for instance, members receive genetic testing, body scans, and a personalized health plan. It considers itself a supplement to your insurance plan, not a substitute for it.

The pros: By virtue of the fact that theyre not bound to a 15-minute reimbursable visit, these doctors can take the time to understand patterns and concerns that arent just todays problem. They also help with stress reduction and recommend healthy eating and exercise programs.

The cons: These physicians can feel like partners in your care, but theyre pricey. Forward runs about $149 a month, and Parsley Health costs about $150 to $250 a month, depending on how many visits a year you want. And the testing and blood work may not be included in the membership fees.

Different wearables can track your heart rate, heart rhythms, blood pressure, and sleep patterns. They also have a hint of Orwellian, Black Mirror creepiness, as some life-insurance companies have started using them to assess an individuals activity level and grant discounts on premiums based on lifestyle. So make sure youre aware of whos watching your watch.

Prostock-StudioGetty Images

The pros: Your wearable may alert you to a heart problem (the Apple Watch Heart Rate app). And the Weill Cornell Alzheimers Prevention Clinic uses the Whoops sleep-activity data to track whether people experience a decrease in REM sleep, a potential risk factor for Alzheimers.

The cons: Wearables can be helpful for monitoring areas of concern, like not getting adequate sleep, but they cant do a doctors work yet. Plus, watch-based EKGs may deliver endless data outputs that send guys in for hours of fruitless worry and testing.

By the start of 2019, more than 26 million Americans had spat into a tube and sent a DNA sample off to a lab to check genetic health risks and ancestry.

The pros: Knowing that your DNA indicates youre at increased risk for certain diseases, including breast cancer (yes, even men can get it), age-related macular degeneration, and blood-clotting disorders, can help you step up efforts to prevent them.

The cons: It can be jarring to receive the news that youre at risk for a disease via a report, and you need to work with a doctor to retest to see if the diagnosis is accuratethen find if what youre doing to ward off a disease is adequate.

See the original post here:

Urgent Care, Telemedicine - Ways Going to the Doctor Is Changing - Men's Health

UVA Honors Its Leading Researchers at Boar’s Head Banquet – University of Virginia

The University of Virginias top leaders gathered Wednesday evening at the Boars Head Resort to honor faculty members from across Grounds for their outstanding contributions to their fields of study and societal impact through their research and scholarly activities.

University of Virginia President Jim Ryan presented the 2019 Research Achievement Awards to 13 UVA faculty members at the dinner event.

This is the first year of the Research Achievement Awards, Vice President for Research Melur Ram Ramasubramanian said. We believe that as a university, we are what we celebrate. We want to acknowledge the talented UVA faculty who are leaders in their fields and are impacting the world in positive ways.

Provost Elizabeth Liz Magill said, Were delighted to have a chance to celebrate the accomplishments and achievements of our faculty. From education policy to precision medicine to police-community relations, there are many different fields and individuals being honored by these awards.

Im awed and immensely grateful for the contributions the award winners have made to their respective fields and to the University of Virginia, Ryan said. Our strategic plan focuses a good deal of attention on supporting research. ... Our ultimate goal is to make it possible for researchers at UVA to do their very best work.

The awards covered excellence in research, collaboration, mentorship, public impact and innovation.

Pompano arrived at UVA in 2014 and assembled a robust research team in her lab. Pursuing new technologies and new questions, she is developing new approaches to study immunity. In the areas of immunoanalysis and immunoenineering, she is working to map out cellular activity in live tissues. Her group was recently awarded a large grant from the National Institutes of Health to develop an artificial lymph node on a microfluidic chip.

Dr. Pompano chose the road less travelled by pursuing entirely new technologies and questions, rather than the safer route of building on the experiences from her Ph.D. or postdoc work, Jill Venton, chair of the Department of Chemistry, said. This strategy required spending the first 2.5 years of her professorship laying new groundwork. Dr. Pompano is a research leader in the fields of analytical chemistry and immunoengineering.

Bassoks work is in early childhood education, and her focus has been to find a way for it to both meet high standards and make a difference in the lives of young children. To do this, she has partnered with policymakers and school districts in Virginia and Louisiana to study how early childhood education opportunities can happen at scale.

In the past four years, her work has accelerated. She has published 16 articles and received more than $6 million in grant funding. In 2017, Bassok was honored with the Presidential Early Career Award for Scientists and Engineers.

Daphna Bassok has raised the bar for the field and will motivate other scholars to do more insightful and rigorous work, said Katherine Magnuson, director of the University of Wisconsins Institute for Research on Poverty.

Alhusens research focuses on improving maternal and early infant health outcomes for disabled women and women living in poverty. Her research has been funded by the National Institutes of Health, the Health Resources and Services Administration and numerous foundations, and the goal of her work is to provide higher quality care to vulnerable populations.

She has received numerous awards for her work, including the Southern Nursing Research Society Early Science Investigator Award; the Association of Womens Health, Obstetric, and Neonatal Nurses Award for Excellence in Research; and School of Nursings Faculty Research Mentor Award.

Walsh is Lockhart B. McGuire Professor of Internal Medicine and directs the School of Medicines Hematovascular Biology Center. His research is focused on clonal hematopoiesis of indeterminate potential, or CHIP.

In his lab, he is looking at how mutations in blood cells lead to chronic diseases like heart attack and stroke. Through precision medicine, he is identifying and combatting the out-of-control multiplying process in these mutations to fight age-related diseases, as well as blood cancers like leukemia.

Walsh has published more than 350 scientific articles and he is the recipient of multiple research grants from the National Institutes of Health, including a MERIT Award. In 2011, the American Heart Association designated him a Distinguished Scientist by for his contributions to cardiovascular research.

Throughout his career, Scullys research, scholarship and teaching have focused on the science of how corrosion occurs and the engineering required to prevent it. He has conducted research and collaborated with scientists around the world in numerous industries such as energy, transportation, infrastructure, aerospace, maritime and microelectronics.

His projects include two U.S. Department of Energy Energy Frontier Research centers, two Department of Defense multi-university research initiatives, as well as grants from the National Science Foundation, PPG Industries and Axalta (formerly DuPont), and the U.S. Office of the Undersecretary of Defense.

Scully, the Charles Henderson Chaired Professor and chair of the Department of Materials Science and Engineering, also co-directs the Center for Electrochemical Science and Engineering, one of the leading centers in the world focusing on materials degradation. The center has generated more than $30 million in research funding in the last 10 years and graduates on average four to five Ph.D. students per year.

Scully is technical editor in chief of CORROSION, The Journal of Science and Engineering, the premier international research journal for the field. He serves in several capacities as an ambassador for the materials-corrosion field, including several meetings to debrief the U.S. Congress on materials degradation issues of national importance.

John Scullys contributions to corrosion can be characterized by quality, quantity and longevity, said Gerald S. Frankel, Ohio State University distinguished professor in materials science and engineering and a member of CORROSIONs editorial board. It is clear that he is a world leader, if not the world leader, in metal passivity, passivity breakdown and localized corrosion, and stress corrosion cracking.

In more his more than 20 years at UVA, Lambert has advanced the science of risk analysis and systems engineering. He has led more than 60 projects related to advanced logistics systems for a total of approximately $25 million in research funding.

Lambert, a professor in the Department of Engineering Systems and Environment, has focused on the disruption of system priorities by emergent and future conditions, including technologies, regulations, markets, environments, behaviors and missions. His work has been applied to disaster resilience, energy infrastructure, coastal protection, economic development, transportation, biofuels and Olympics planning, among other challenges.

His research has been cited more than 5,000 times across more than 200 publications. In 2019, he chaired the Fifth World Congress on Risk, convening more than 300 scientists in Cape Town, South Africa.

Professor Lambert is among the most accomplished and respected scientists of systems engineering and risk analysis in the world today, said Igor Linkov, Risk and Decision Science Team Lead for the U.S. Army Engineer Research and Development Center. Lambert in his research invented the application of scenario-based preferences in risk analysis.

Connelly, Morris and Grossman worked together on a multi-disciplinary project to examine how early life experiences affect the brain and social behaviors. The team studies the brain, as well as social and cognitive development, during the first two years of life, focusing on oxytocin and its role in social behavior. Their research has helped to illuminate gaps in our knowledge about behavioral development in humans, and helps us better understand healthy and atypical development.

They received a National Science Foundation Research Award in 2017 for their cutting-edge approach in combining epigenetic, neuroscience and behavioral methods across their three labs, and their work has led to several publications.

Moore is a busy physician-scientist with his own lab, and has recently become the division chief of Pediatric Gastroenterology, Hepatology, & Nutrition at UVA. He also co-wrote the application for a Trans-University Microbiome Initiative grant, which was funded last year by the Universitys Strategic Investment Fund in an effort to make UVA a center for microbiome research. But that has not stopped him from repeatedly aiding his colleagues and providing them with key resources when they needed them.

Three colleagues joined forces to nominate Moore for the mentorship award, mentioning his critical support, his generous sponsorship and advice, and his guidance as they dealt with grant applications and the logistics of their first accepted grants. Moore went above and beyond, donating lab space and reaching out to his networks to help them make the connections and give them a leg up in their careers.

Williams only arrived at Batten two years ago, but after the violent Unite the Right rally in Charlottesville in August 2017 he was able to immediately show the value of his research and public service engagement to the University community.

Starting before he came to the University, he has spent two decades doing research in the field on police-community relations around racial profiling, community policing and the need for law enforcement officers to work with their community on issues of public safety. In all his work, he strives to make an impact on communities by building relationships and tackling problems wherever they crop up.

Dr. Williams consistently uses his knowledge, experience and passion for the good of our city, Mindy Goodall, executive director of the Charlottesville Police Foundation, said. Charlottesville is fortunate to have gained him as a citizen and champion of police and community reconciliation.

The award for Innovator of the Year was presented to Dillingham and Ingersoll for their creation of PositiveLinks, an application designed to improve health outcomes and care for people living with HIV. They will give deliver a keynote lecture Feb. 18 in the Rotunda Dome Room.

Other researchers (in alphabetical order by school) were honored for being the top 25 in sponsored funding, top cited, national award winners, named to a national academy, or named as an outstanding researcher for their school:

Timothy Beatley, PlanningBarbara Brown Wilson, PlanningMona El Khafif, Urban & Environmental Planning

Jessica Connelly, PsychologyRita F. Dove, EnglishKevin Everson, ArtTobias Grossman, PsychologyL. Ilse Cleeves, AstronomyNitya Kallivayalil, AstronomyLee M. Lockwood, EconomicsJames P. Morris, PsychologyKen Ono, MathematicsRebecca R. Pompano, ChemistryMarilyne Stains, ChemistryAlan S. Taylor, History

Christopher Barrett, Director

David G. Mick, Marketing

Derrick P. Alridge, Leadership, Foundations and PolicyDaphna Bassok, Leadership, Foundations and PolicyRobert Q. Berry, Instruction and Special EducationCatherine Bradshaw, Human ServicesBenjamin L. Castleman, Leadership, Foundations and PolicyNancy L. Deutsch, Youth-NexJason Downer, Human ServicesSara E. Rimm-Kaufman, Leadership, Foundations and PolicyWilliam J. Therrien, Instruction and Special EducationArt Weltman, KinesiologyJoanna Lee Williams, Leadership, Foundations and PolicyAmada P. Williford, Human Services

Thomas H. Barker, Biomedical EngineeringHilary Bart-Smith, Mechanical and Aerospace EngineeringCraig H. Benson, Environmental EngineeringSteven M. Bowers, Electrical and Computer EngineeringJames T. Burns, Materials ScienceBenton H. Calhoun, Electrical and Computer EngineeringJoe C. Campbell, Electrical and Computer EngineeringGeorge J. Christ, Biomedical EngineeringJason L. Forman, Center for Applied BiomechanicsJeffery W. Holmes, Biomedical EngineeringPatrick E. Hopkins, Mechanical and Aerospace EngineeringKevin A. Janes, Biomedical EngineeringJames H. Lambert, Systems and EnvironmentXiaodong (Chris) Li, Mechanical and Aerospace EngineeringPamela M. Norris, Mechanical and Aerospace EngineeringElizabeth J. Opila, Materials ScienceMatthew B. Panzer, Mechanical and Aerospace EngineeringJohn R. Scully, Materials ScienceKevin Skadron, Computer ScienceMary Lou Soffa, Computer ScienceJohn A. Stankovic, Computer ScienceMalathi Veeraraghavan, Electrical and Computer Engineering

Brian N. Williams, Public PolicyJay Shimshack, Research Dean

Jayakrishna Ambati, OphthalmologyRuth Bernheim, Public Health SciencesAlison K. Criss, Microbiology /GIDIRebecca Dillingham, Infectious DiseasesLinda R. Duska, Obstetrics/Gynecology OncologyAnindya Dutta, Biochemistry/Molecular GeneticsW. Jeff Elias, NeurosurgeryEdward H. Egelman, Biochemistry/Molecular GeneticsRobin A. Felder, Clinical PathologyEric R. Houpt, Infectious DiseasesKaren Ingersoll, Psychiatry and Neurobehavioral SciencesKaren C. Johnston, NeurologyJaideep Kapur, NeurologyAnne K. Kenworthy, Molecular Physics and BiophysicsJonathan Kipnis, NeuroscienceRobert C. Klesges, Public Health SciencesBoris P. Kovatchev, Psychiatry and Neurobehavioral SciencesThomas P. Loughran, Oncology and MedicineColeen A. McNamara, Internal and Cardiovascular MedicineWladek Minor, Molecular Physics and BiophysicsSean R. Moore, PediatricsJames P. Nataro, PediatricsImre Noth, Internal and Pulmonary MedicineMark D. Okusa, NephrologyGary K. Owens, Cardiovascular Research, Molecular Physiology and Biological PhysicsKevin A. Pelphrey, NeurologyWilliam A. Petri, Internal Medicine and Infectious DiseasesKodi S. Ravichandran, MicrobiologyPatricio E. Ray, PediatricsStephen S. Rich, Public Health SciencesLukas K. Tamm, Molecular Physics and BiophysicsGregory C. Townsend, Internal Medicine and Infectious DiseasesKenneth Walsh, Internal and Cardiovascular MedicineKatharine Hsu Wibberly, Public Health SciencesMichael C. Wiener, Molecular Physics and BiophysicsMark Yeager, Molecular Physics and BiophysicsJames C. Zimring, Pathology

Jeanne L. Alhusen, Nursing

View original post here:

UVA Honors Its Leading Researchers at Boar's Head Banquet - University of Virginia

Meet the Ex-Dallas Doctor Now Playing a Doctor on TV During the Super Bowl – D Magazine

When you briefly glimpse Calvin Peters in a Verizon commercial during Super Bowl LIV on Sunday, his face might seem familiar.

Maybe you remember him from his performances during the audition stage of American Idol. Perhaps you recognize him from guest appearances in television dramas such as 9-1-1 or Snowfall. Or possibly he was your doctor during an appointment at UT Southwestern Medical Center.

The diverse resume for the former Dallas physician now finds him splitting much of his time between treating patients and auditioning for roles on stage and screen.

The art caters to my right brain, and the medicine and science is challenging and fostering my left brain, Peters said. I love helping people. Every time I look in a patients eyes and theyre hurting, that tugs at my heart in a way that nothing else can. But then I love to be on stage and perform.

Appropriately enough, Peters plays a surgeon in the Verizon spot that will debut Sunday. Its a continuation of the companys ongoing campaign saluting first responders and was directed by Hollywood filmmaker Peter Berg (Friday Night Lights).

Hes a visionary. It was so encouraging and motivating to see this guy work, Peters said. I want to continue to grow to where Im working with all kinds of creative talent.

Peters developed a passion for medicine and for performing while growing up in the Stop Six neighborhood in Fort Worth. He acted in his first play at age 9, and later graduated from North Side High School.

At Hampton University in Virginia, Peters was involved in musical theater before graduating with a degree in molecular biology in 2006.

He returned to Texas to attend medical school at UT Southwestern, then stayed to complete his residency in 2014, specializing in physical medicine and rehabilitation.

During his residency, he impulsively auditioned for American Idol, eventually making the show in 2013. Later that year, he appeared on an episode of The Dr. Oz Show spotlighting the Most Eligible Doctors. He was hooked.

I was still going to work every day, and everybody at the hospital was really supportive, but I still felt empty, he said.

So Peters took some classes and hired an agent in Dallas, and began acting in local commercials and short films. In 2015, he relocated to Los Angeles and set up his practice primarily as a therapist for nursing home patients, which allowed him to have a flexible schedule.

As his exposure grew, Peters refined his craft with improvisation classes, voice classes, and dance classes. He hired a manager and began booking jobs, including an episode of Snowfall that aired in August and a small role on 9-1-1 in November. Peters also plays a waiter in the low-budget romantic comedy What Love Looks Like, which began streaming on Amazon Prime earlier this month.

Juggling his two careers has become more of a challenge. Peters recently had an opportunity to play Harpo in a traveling stage production of The Color Purple, but couldnt commit to the full year away from his practice.

His circumstances mean Peters isnt be as desperate as other up-and-coming actors in California, but he said hes just as driven. He spends 30-40 hours per week reading scripts and rehearsing.

My bills are all paid. Im still saving money and have health insurance. I have an assistant. I live in Beverly Hills. My life is not bad, Peters said. But when I go into an audition, Im still going hard. Im giving it my all. Im putting my foot in the water just as fast and hard as somebody whos waiting tables.

Eventually, he would like to give back to the rough neighborhood in eastern Fort Worth where he was raised, and where his family has been victimized by a pervasive cycle of drugs and violence.

Ill always be connected to that community. Im never going to act like Im too good for them. Fort Worth will always be in my heart, he said. Sometimes its so difficult to go be around some of the situations because the energy and the vibes are not right. The way I grew up was not ideal, but I feel so fortunate.

As his success in show business grows and he plans for the long-term future, Peters said he hasnt thought about abandoning his career in medicine.

I dont think you can ever stop somebody from being a doctor, Peters said. I try not to think about that right now, because I dont have to make that choice yet. If the situation got big enough, I probably wouldnt be able to go into a hospital and practice, but theres always a way to stay connected to healthcare.

The rest is here:

Meet the Ex-Dallas Doctor Now Playing a Doctor on TV During the Super Bowl - D Magazine

Realizing The Full Potential Of Precision Medicine In Oncology – Contract Pharma

Precision medicine promises a new paradigm in oncology where every patient receives truly personalized treatment. This approach to disease diagnosis, treatment and prevention utilizes a holistic view of the patientfrom their genes and their environment to their lifestyleto make more accurate decisions.

Growing at a rate of 10.7 percent, the precision medicine market is expected to exceed $96 billion by 2024.1 Bioinformatics represent a significant share of the market, as bioinformatics tools enable the data mining necessary for rapid identification of new drug targets and repurposing of existing treatments for new indications.1 (Reuters) The oncology segment of the precision market is expected to experience an 11.1 percent compounded annual growth rate (CAGR) leading up to 2024 due to the success of recent targeted therapies and subsequent high demand.

Still, precision medicine is in its infancy, and making personalized treatment a reality for all patients requires a transformation in how novel therapies are developed and delivered. New regulatory, technical, clinical and economic frameworks are needed to ensure that the right patients are able to access the right therapy at the right time. In this article, we review the current state of precision medicine in oncology and explore some of the challenges that must be addressed for precision medicine to reach its full potential.

Great strides toward precision medicine are being made in the area of cancer immunotherapy, which is designed to boost a patients own immunity to combat tumor cells. The introduction of immune checkpoint inhibitors (PD-1/PD-L1 and CTLA-4 inhibitors) revolutionized treatment for certain hematologic malignancies and solid tumors. To date, immune checkpoint inhibitors have been approved by the U.S. Food and Drug Administration (FDA) for more than 15 cancer indications, but their widespread use has been hampered by unpredictable response rates and immune-related adverse events.

The approvals of the first chimeric antigen receptor (CAR)-T cell (CAR-T) therapies in 2017 were the next leap forward in precision medicine. These immunotherapies demonstrated that it was possible to take out a patients own T-cells, genetically modify them, and then put them back in to target cancer cells. With complete remission rates as high as 83 percent within three months of treatment, CAR-T therapies represent a seismic shift in our approach to cancer, bringing the elusive possibility of a cure one step closer. However, longer-term follow-up has shown that these remissions may not be durable2 and prevention of relapse must still be studied.

Ultimately, the goal of cancer immunotherapy is to stimulate the suppressed immune system of a patient with cancer so that it can launch a sustained attack against tumor cells.3 This is complicated, as the interactions between tumors and immune systemsometimes called the Cancer-Immunity Cycle (see Figure 1 in the slider above)4are complex and dynamic. The Cancer-Immunity Cycle manages the delicate balance between the immune systems ability to recognize non-self and the development of autoimmunity.

In some cases, the immune system may fail to recognize tumor cells as non-self and may develop a tolerance to them. Moreover, tumors have an armamentarium of methods for evading the immune system. Given this elaborate interplay between cancer and immunity, there is a wide range of potential cancer immunotherapy approaches:

The immune response to cancer involves a series of carefully regulated events that are optimally addressed as a group, rather than individually.4 The complexity of the immune response to cancer provides a strong rationale for combination therapies, for instance:

Increasingly, the development and deployment of immunotherapy relies on harnessing genomic data to identify the patients most likely to respond to immunotherapy and to customize immunotherapy for a given patient.6 Thus, molecular profiling technologies, such as next-generation sequencing, have become integral to drug development and patient selection. At the same time, researchers are focusing on identifying molecular alterations in tumors that may be linked to response.7 The molecular fingerprints of a tumor can be quite complex and heterogeneous, not only across tumors, but also within a single patient. Consequently, molecular tumor characterization requires both multidimensional data from laboratory and imaging tests and advanced software and computational methods for analyzing these data.8 This emergence of computational precision oncology is associated with both opportunities and challenges, from validation and translation to regulatory oversight and reimbursement.

The regulatory landscape is evolving to keep pace with technological advances in cell engineering and gene editing. Since 2013, the FDA has published four guidance documents on cellular and gene therapy products, as well as two guidance documents providing recommendations on regenerative medicine advanced therapies (RMATs). Specifically, their Expedited Programs for Regenerative Medicine Therapies for Serious Conditions, published in November 2017, provides guidance on the expedited development and review of regenerative medicine therapies for serious or life-threatening diseases and conditions. This document also provides information on the use of the accelerated approval pathway for therapies that have been granted the RMAT designation.9

In the EU, the European Medicines Agency (EMA) published a draft revision of its Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells in July 2018.10 This draft revision includes current thinking on the requirements for nonclinical and clinical studies, as well as specific sections on the scientific principles and clinical aspects of CAR-T products.

Precision medicines such as CAR-T therapies require manufacturers to transform a complex, individualized treatment into a commercial product. In conventional manufacturing, the entire manufacturing process occurs within the confines of the manufacturing facility. With cell therapies, however, the process begins with the collection of cells from the patient and ends with administration of the final product (see Figure 2 in the slider above). In between, the cells are handed off multiple times for the process of genetic modification, creating a complex supply chain that blends manufacturing and administration.11

Moreover, in contrast to traditional manufacturing where the starting materials are standardized or well-defined, the starting materials for cell therapies are derived from patients and, thus, highly variable.

As evidenced by the manufacturing challenges that plagued the launch of Kymriah (tisagenlecleucel), even pharmaceutical giants have struggled with meeting label specifications for commercial use.13 To help address its manufacturing hurdles, Novartis acquired CellforCure, a contract development manufacturing organization, and plans to transform by focusing on data and digital technologies.14,15 What this means for sponsors is that robust, scalable manufacturing must be incorporated into clinical developing planning at its earliest stages.

The high price tags associated with CAR-T therapies illustrate how expensive targeted therapies are in comparison to their traditional counterparts.16 Existing health insurance models have not been structured to reimburse for costly treatments that offer the potential for long-term benefit or even cure. The pricing model for CAR-T therapies may be especially challenging for private insurance companies, which have higher turnover and shorter coverage windows than national health insurance programs. For sponsors of precision medicine therapies, one way to address the challenge of reimbursement is to create innovative, value- or outcomes-based pricing models, rather than focusing on sales volume. The success of these new pricing models will rely on patient selection. To demonstrate value and optimizing outcomes, sponsors will need to develop profiles of patients who are most likely to respond and provide tools for identifying these patients.8

Of note, on August 7, 2019, the Centers for Medicare & Medicaid Services (CMS) finalized the decision to cover FDA-approved CAR-T therapies when provided in healthcare facilities enrolled in the FDA risk evaluation and mitigation strategies (REMS) for FDA-approved indications. Medicare will also cover FDA-approved CAR-T treatments for off-label uses that are recommended by CMS-approved compendia.17

Beyond the pharmaceutical companies that are working to develop personalized treatments, the precision medicine ecosystem has a number of other key stakeholdersregulators, payers, diagnostic companies, healthcare technology companies, healthcare providers and, of course, patients. Pharmaceutical companies need to engage with each of these stakeholders by providing education or developing partnerships that help demonstrate the need for high-quality data collection, the value of precision medicine, and the process for identifying the right patients.

Sponsors may also benefit from engaging with patient advocacy groups as these groups play a critical role in connecting patients and caregivers with scientific and healthcare experts to learn about how new immunotherapy breakthroughs are changing the standard of care.

Empowered patients pushing for the latest innovations are propelling precision medicine forward, but we still have a way to go before the full potential of precision medicine is realized. In its maturity, precision medicine will not only enable the personalization of treatments for individual patients, but also inform public health at a population level as insights from the genetic and molecular data collected are used to advance our understanding of disease. Robust data collection and analysis, along with standardization, are required for building this foundation of precision medicine, and multi-stakeholder buy-in is necessary for addressing issues around data integration and privacy.

While significant challenges remain, the opportunity to transform patient outcomes and population health with precision medicine is tantalizing. Increasingly, we are seeing advanced technologiessuch as artificial intelligence and machine learningbeing incorporated into the drug discovery and development process. This underscores the critical need for a multidisciplinary approach to precision medicine, from discovery at the bench all the way through to delivery at the bedside, to help ensure that more patients can access the right therapy at the right time, and the right price.

References

View post:

Realizing The Full Potential Of Precision Medicine In Oncology - Contract Pharma

Triple negative breast cancer might not actually be ‘breast cancer’ – Clinical OMICs News

A new study from New York might completely change how breast cancer is classified and treated. Researchers have discovered, in a study of triple negative breast cancer in black women, that the molecular mechanisms involved are more closely related to non-breast cancers, and two specific gene mutations may be responsible for the tumor development.

This study would signal a potential treatment breakthrough for patients with this form of breast cancer, which disproportionately affects and tends to develop more aggressively in black women. Triple negative breast cancer is a form of breast cancer that is not hormone driven, and it does not express the estrogen receptor, progesterone receptor, or HER2/neu genesunlike other forms of the disease, which rely on hormone-driven therapies to control the cancer.

The paper, authored by researchers at The Graduate Center of The City University of New York, Hunter College, Memorial Sloan Kettering Cancer Center, and the University of Chicago, details findings about the interaction between two specific genes during DNA replication that appear to drive growth of malignant cells in patients with triple negative breast cancer.

The research team found the presence of a mutated p53 (a tumor suppressor gene whose mutation often leads to cancer development) and a mutated PARP (a gene that maintains DNA integrity) in a large majority of patients with triple negative breast cancer. Specifically, they found that p53 would interact with replicating DNA and PARP, driving cell growth and division.

This information would suggest that if drugs could specifically target these two mutated genes and the proteins they produce, it would be possible to suppress their actions and slow or stop tumor growth, so the researchers tested this in lab, using drugs developed for other types of cancer.This was indeed the case.

Our new findings suggest that the presence of both [p53] and PARP could serve as a good identifier of breast cancers that would respond to combined treatment with talazoparib a PARP inhibitor that was developed to treat breast cancers with the BRCA mutation and temozolomide a chemotherapy agent that is used to treat some brain cancers, said Professor Jill Bargonetti, whose lab conducted the research. This is an exciting finding because it could lead to the first targeted therapy for triple negative breast cancer, enabling more precise and effective treatment of a very aggressive form of the disease.

To conduct this study, researchers investigated a variety of breast cancer cell lines, patient-derived xenographs, tissue microarray samples, and data from The Cancer Genome Atlas to tease out the association and interaction between p53 and PARP in triple negative breast cancer.

Our findings that mutant p53 and PARP participate in the DNA replication pathway will provide mechanism-derived dual biomarkers that aid in the diagnosis and treatment of these therapeutically elusive subsets of breast cancer, said Gu Xiao, a research associate with Bargonettis lab and the papers first author.

The scientists had discovered that high levels of these proteins are present on replicating DNA in these types of tumors, suggesting that the unusual presence and levels of these proteins may drive tumor growth. When these researchers reviewed the therapeutic mechanisms of existing cancer drugs, it led the research team to identify talazoparib and temozolomide as existing drugs that could potentially be combined to create a targeted therapy that could effectively suppress the growth of triple negative breast cancer tumors.

Looking to the future, this group plans to test if this combination of drugs can successfully block replication of triple negative breast cancer cells in xenographed animal models. If the therapy can prove to be successful, it would very likely lead to the reclassification of triple negative breast cancer to a category of cancers called mutant p53/PARP1 positive cancers, which are treatable with a combination PARP inhibitor therapies.

With so little in positive news for this particular subset of breast cancer, and many previous clinical trials being disappointing, these new findings are both welcome news to the scientific community, as well as a good explanation as to why this disease has been so hard to treat compared to other forms of breast cancer.

This study gives doctors two new biomarkers to test for in patients, and many new potentials in clinical trials, which can be fast tracked since so many drugs already exist that target these specific genes. While this study only tested out two drugs, there are many other drugs that specifically target p53 and PARP, and many more which can be developed, which may give even better results. Hopefully, there will be many new, positive developments for this disease following this discovery.

View original post here:

Triple negative breast cancer might not actually be 'breast cancer' - Clinical OMICs News

Is Predictive Technology Group Inc (OTCMKTS:PRED) Ready for Another Run? – The Oracle Dispatch

Predictive Technology Group Inc (OTCMKTS:PRED) just announced that it and Atrin Pharmaceuticals LLC areentering into a collaboration agreement to develop molecular diagnostic toolsto facilitate improved selection of cancer patients who would most benefit fromtreatment with DNA Damage and Response (DDR) inhibitors, including Atrins andother small molecule ATR inhibitors.

According to the release, Atrinand Predictive will jointly utilize Predictive Laboratories state-of-the-artsequencing capabilities and genomics expertise to identify cancer patients withspecific molecular markers that predict the level of clinical response toAtrins, and other, targeted therapies. This is intended to improve patientoutcomes as well as improve Atrins ability to successfully progress itsproduct pipeline, and upon commercialization, improve on the treatments forwomen with cancer.

Predictive Technology GroupInc (OTCMKTS:PRED) promulgates itself as a company that, together with itssubsidiaries, develops and commercializes discoveries and technologies involvedin novel molecular diagnostic and pharmaceutical therapeutic/human cells,tissues, and human cellular and tissue-based products (HCT/Ps).

The company operates throughtwo segments, Regenerative Medicine Products and HCT/Ps, and Diagnostics andTherapeutics. It offers ARTguide, a genetic diagnostic and prognostic test forwomen experiencing infertility as a result of endometriosis and other healthconcerns; and regenerative medicine products, including AmnioCyteT, AmnioCytePlusT, PolyCyteT, and CoreCyteT.

The company was formerly knownas Global Enterprises Group, Inc. and changed its name to Predictive TechnologyGroup, Inc. in July 2015. Predictive Technology Group, Inc. was founded in 2005and is headquartered in Salt Lake City, Utah.

According to companymaterials, Predictive Technology Group aims to revolutionize patient carethrough predictive data analytics, novel gene-based diagnostics and companiontherapeutics through its subsidiaries Predictive Therapeutics, PredictiveBiotech, and Predictive Laboratories. These subsidiaries are focused onendometriosis, scoliosis, degenerative disc disease and human cell and tissueproducts. The subsidiaries use genetic and other information as cornerstones inthe development of new diagnostics that assess a persons risk of illness andtherapeutic products designed to identify, prevent and treat diseases moreeffectively.

Find out when $PRED reaches critical levels. Subscribe toOracleDispatch.com Right Now by entering your Email in the box below.

As noted above, PRED just announced that it and Atrin Pharmaceuticals LLC are entering into a collaboration agreement to develop molecular diagnostic tools to facilitate improved selection of cancer patients who would most benefit from treatment with DNA Damage and Response (DDR) inhibitors, including Atrins and other small molecule ATR inhibitors.

Weve witnessed 36% piled onfor shareholders of the listing during the trailing month. In addition, thename has witnessed a pop in interest, as transaction volume levels haverecently pushed 11% above the average volume levels in play in this stock overthe longer term.

We are very pleased to workwith Atrin Pharmaceuticals, a recognized leader in the development ofanti-cancer therapeutics targeting DDR, said Bradley Robinson, president andchief executive officer of Predictive Technology Group. We see an opportunityto develop a precision medicine approach to address unmet medical needs bycombining our state-of-the-art sequencing capabilities, genomics expertise andcompanion diagnostics with Atrins targeted therapeutics. This collaboration isconsistent with our vision of building a leading womens health platform, andwe look forward to working together on this important initiative.

Currently trading at a marketcapitalization of $276M, PRED hasa chunk ($842K) of cash on the books, which stands against about $8.6M in totalcurrent liabilities. PRED is pulling in trailing 12-month revenues of $43.7M.In addition, the company is seeing major top-line growth, with y/y quarterlyrevenues growing at 2.4%. You can bet we will update this one again as newinformation comes into view. Sign-up forcontinuing coverage on shares of $PRED stock, as well as other hot stock picks,get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in $PRED, either long orshort, and we have not been compensated for this article.

You have Successfully Subscribed!

Post Views: 175

Visit link:

Is Predictive Technology Group Inc (OTCMKTS:PRED) Ready for Another Run? - The Oracle Dispatch

OpGen (NASDAQ:OPGN) and Avant Diagnostics (NASDAQ:AVDX) Head-To-Head Review – Riverton Roll

OpGen (NASDAQ:OPGN) and Avant Diagnostics (OTCMKTS:AVDX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Profitability

This table compares OpGen and Avant Diagnostics net margins, return on equity and return on assets.

Volatility and Risk

OpGen has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, Avant Diagnostics has a beta of 9.42, suggesting that its stock price is 842% more volatile than the S&P 500.

Earnings & Valuation

This table compares OpGen and Avant Diagnostics revenue, earnings per share and valuation.

Avant Diagnostics has lower revenue, but higher earnings than OpGen.

Analyst Recommendations

This is a breakdown of current ratings and target prices for OpGen and Avant Diagnostics, as reported by MarketBeat.com.

OpGen presently has a consensus target price of $7.93, suggesting a potential upside of 405.31%. Given OpGens higher probable upside, equities research analysts plainly believe OpGen is more favorable than Avant Diagnostics.

Insider & Institutional Ownership

0.3% of OpGen shares are held by institutional investors. Comparatively, 0.0% of Avant Diagnostics shares are held by institutional investors. 5.0% of OpGen shares are held by insiders. Comparatively, 38.0% of Avant Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Avant Diagnostics beats OpGen on 7 of the 11 factors compared between the two stocks.

About OpGen

OpGen, Inc., a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. The company's products include Acuitas AMR Gene Panel, a vitro diagnostic test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance in urine specimens or bacterial colonies isolated from urine and other body sites; and QuickFISH and PNA FISH products, which are FDA-cleared and CE-marked diagnostic test designed to detect antimicrobial- resistant pathogens. In addition, it offers Acuitas Lighthouse informatics systems, a cloud-based HIPAA compliant informatics offerings, which combine clinical lab test results with patient and hospital information, and provide analytics and insights to enable manage MDROs in the hospital and patient care environment. The company was incorporated in 2001 and is headquartered in Gaithersburg, Maryland.

About Avant Diagnostics

Avant Diagnostics, Inc., a commercial-stage molecular data-generating company, focuses on the development and commercialization of proprietary data-generating assays that provide information for physicians and patients in the areas of cancers. It owns license and distribution right for OvaDx, a noninvasive proteomics diagnostic screening test for the early detection of ovarian cancer. The company was founded in 2009 and is based in Washington, District of Columbia.

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.

More:

OpGen (NASDAQ:OPGN) and Avant Diagnostics (NASDAQ:AVDX) Head-To-Head Review - Riverton Roll

The Global Market for Sample Preparation in Genomics, Proteomics and Epigenomics is Projected to Reach $7.7 Billion by 2021, Growing at a CAGR of 6.5%…

DUBLIN--(BUSINESS WIRE)--The "Sample Preparation in Genomics, Proteomics, and Epigenomics: Global Markets" report has been added to ResearchAndMarkets.com's offering.

This research report categorizes the market for sample preparation in genomics, proteomics and epigenomics by product segment. The major product segments are instruments, consumables, accessories and sample preparation kits. The instruments segment is subdivided into workstations, liquid handling systems, extraction systems and other instruments. Consumables are divided into columns, filters, tubes, plates and other consumables. Sample preparation kits are segmented into purification kits, isolation kits, extraction kits and others.

The global market for sample preparation is segmented by end user into research centers, academic institutes, and government institutes, hospitals and clinics, pharmaceutical and biotechnology companies and others. The markets in North America, Europe, Asia-Pacific and rest of the world are covered. The market is also segmented by application into genomics, proteomics and epigenomics.

The Report Includes:

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market Overview

Chapter 4 Global Market for Sample Preparation in Genomics, Proteomics and Epigenomics by Product Segment

Chapter 5 Global Market for Sample Preparation in Genomics, Proteomics and Epigenomics by Application Segment

Chapter 6 Global Market for Sample Preparation in Genomics, Proteomics and Epigenomics by End User

Chapter 7 Global Market for Sample Preparation in Genomics, Proteomics and Epigenomics by Region

Chapter 8 Company Profiles

Chapter 9 Competitive Landscape

For more information about this report visit https://www.researchandmarkets.com/r/j4pqkx

Excerpt from:

The Global Market for Sample Preparation in Genomics, Proteomics and Epigenomics is Projected to Reach $7.7 Billion by 2021, Growing at a CAGR of 6.5%...

Australia Day Honours list celebrates staff and alumni – News – The University of Sydney

StaffCompanion (AC) in the General Division of the Order of Australia

Professor Bruce Gregory Robinson AM (MBBS 80 MSc 83 MD 91)For eminent service to medical research, and to national healthcare, through policy development and reform, and to tertiary education.

Professor Peter Joseph McCluskeyFor distinguished service to ophthalmology, and to medical education, to eye health organisations, and to the community.

Emeritus Professor Jules Mitchell Guss (BSc 67 PhD 70)For distinguished service to education and scientific research in the field of molecular bioscience, and to professional organisations.

Dr Stephen Bourke For significant service to the international community of Jordan through archaeologicalprojects.

Professor Pierre Henri ChapuisFor significant service to medical education, and to colorectal surgery.

Professor Richard de DearFor significant service to education, particularly the design of the built environment.

Associate Professor Nicholas John EvansFor service to medicine in the fields of gastroenterology and hepatology.

Dr Meng Chong NguFor service to medicine in the fields of gastroenterology and hepatology.

Her Excellency the Honourable Margaret Joan Beazley AO QC (LLB 74 LLD 08)For eminent service to the people of New South Wales, particularly through leadership roles in the judiciary, and as a mentor of young women lawyers.

Professor Margaret Elaine Gardner AO (BEc 76 PhD 84)For eminent service to tertiary education through leadership and innovation in teaching and learning, research and financial sustainability.

Ms Ilana Rachel Atlas (LLM 87)For distinguished service to the financial and manufacturing sectors, to education, and to the arts.

Dr John Michael Bennett AM (LLM 64 BA 66 LLB 69 LLD 90 Dlitt 07)For distinguished service to the law through prolific authorship of biographies of eminent members of the legal profession.

Professor Robert Graham Cumming (MD 17)For distinguished service to medical education and research, particularly to ageing and age-related diseases.

Mr Kevin McCann AM (BA 61 LLB 64)For distinguished service to business, to corporate governance, and as an advocate for gender equity.

Professor John Reginald Piggot (BA 70)For distinguished service to education, to population ageing research, and to public finance policy development.

Professor Robert (John) Simes (Bsc (Med) 74 MBBS 76 MD 88)For distinguished service to education, and to medicine, in the field of cancer research and clinical trials.

Dr Robyn Williams AM (DSc 88 D.Sc(Honoris Causa) 88)For distinguished service to science as a journalist, radio presenter and author, and to education.

Mr Anthony Abrahams (BA 56 LLB 59)For significant service to Australia-France relations, and to the law.

Emeritus Professor Thomas (John) Boulton (MMedHum 10)For significant service to medical education, and to paediatric medicine.

Emeritus Professor Richard Laurence Broome (PhD 75)For significant service to education in the field of history, and to historical groups.

The Honourable Dr Meredith Anne Burgmann (BA 69 MA 74)For significant service to the people and Parliament of New South Wales.

Dr Graham John Faichney (MAgr 63)For significant service to science in the fields of animal nutrition and physiology.

Emeritus Professor John Joseph Fitzgerald (BA 80)For significant service to higher education, particularly in the field of Chinese studies.

Dr Robyn Rae Iredale (BA 66 DipEd 67)For significant service to people with an intellectual disability, and to education.

Mr David Harley Jacobs (BEc 74)For significant service to Australia-Japan relations, and to business.

Professor Margaret Anne Jolly (BA 70 PhD 80)For significant service to education, particularly to gender and Pacific studies.

Dr David Ronald Leece PSM RFD ED (BScAgr 64 MAgr 68)For significant service to the environment, and to defence and security studies.

Dr Qazi Ashfaq Ahmad (PhD 76)For service to the Muslim community, and to interfaith relations.

Mrs Diana Joy Alexander (Med 99)For service to education, and to the community of Lockhart.

Dr Ian Melvyn Chung (MBBS 63)For service to the law, to medicine, and to the community.

Mrs Robyn Madelon Claydon (MA 79)For service to education, and to the Anglican Church of Australia.

Dr Phillip Seldon Cocks (MBBS 73)For service to medicine, and to medical associations.

Ms Marie Ann Ficarra (BSc 76)For service to the people and Parliament of New South Wales.

Mr Alan Claude Locke (BE(Mech) 63)For service to the community through charitable organisations.

Mr Robert Peter Selinger (BA 69 Med 75)For service to the community, and to education.

Mr John Stewart Stoddart (BArch 59)For service to the performing arts as a designer.

Dr Mark Tredinnick (BA 84 LLB 86)For service to literature, and to education.

Dr Treve Williams (BVSc 65)For service to veterinary science.

Ms Vicki Telfer (MPA 02 MAdminLawPol 10)For outstanding public service to industrial relations policy and reform in New South Wales.

Follow this link:

Australia Day Honours list celebrates staff and alumni - News - The University of Sydney

Current research: 2020 Latest Report on Exosome Diagnostics Market Report Technologies, Analyze the Pipeline Landscape and Key Companies – WhaTech…

Exosome Diagnostics Market Report analysis including industry Overview, Country Analysis, Key Trends, Key Retail Innovations, Competitive Landscape and Sector Analysis for upcoming years.

ReportsnReports added a new report on The Exosome Diagnostics Market Technologies report delivers the clean elaborated structure of the Report comprising each and every business related information of the market at a global level. The complete range of information related to the Exosome Diagnostics Market Technologies is obtained through various sources and this obtained the bulk of the information is arranged, processed, and represented by a group of specialists through the application of different methodological techniques and analytical tools such as SWOT analysis to generate a whole set of trade based study regarding the Exosome Diagnostics Market Technologies.

Download a Free PDF Sample of Exosome Diagnostics Market Technologies Research Report at:

http://www.reportsnreports.com/contactme=1781607

Top Companies mentioned in this report are Capricor Therapeutics Inc, Evox Therapeutics Ltd, ReNeuron Group Plc, Stem Cell Medicine Ltd, Tavec Inc, Codiak Biosciences Inc, Therapeutic Solutions International Inc, ArunA Biomedical Inc, Ciloa 85.

This latest report is on Exosome Diagnostics Market Technologies which explores the application of exosome technologies within the pharmaceutical and healthcare industries. Exosomes are small cell-derived vesicles that are abundant in bodily fluids, including blood, urine and cerebrospinal fluid as well as in in vitro cell culture.

These vesicles are being used in a variety of therapeutic applications, including as therapeutic biomarkers, drug delivery systems and therapies in their own right. Research within this area remains in the nascent stages, although a number of clinical trials have been registered within the field.

Exosomes have several diverse therapeutic applications, largely centering on stem cell and gene therapy.

Exosomes have been identified as endogenous carriers of RNA within the body, allowing for the intracellular transportation of genetic material to target cells.

As such, developers have worked to engineer exosomes for the delivery of therapeutic miRNA and siRNA-based gene therapies. As RNA is highly unstable within the body, a number of different biological vector systems have been developed to enhance their transport within the circulation, including viruses and liposomes.

Similarly, exosomes derived from stem cells have also been identified for their therapeutic applications, particularly in the treatment of cancer and cardiovascular disease. Exosome technologies offer several advantages over existing biologic-based drug delivery systems.

Reasons to buy this Report:

Develop a comprehensive understanding of exosome technologies and their potential for use within the healthcare sector, Analyze the pipeline landscape and gain insight into the key companies investing in exosomes technologies, Identify trends in interventional and observational clinical trials relevant to exosomes.

Get this Report @ http://www.reportsnreports.com/purchasme=1781607

Scope of this Report:

What are the features of the exosome lifecycle?,How are therapeutic exosomes prepared?,How do exosome therapies in development differ in terms of stage of development, molecule type and therapy area?,Which companies are investing in exosome technologies?,How many clinical trials investigate exosomes as biomarkers, therapeutics and vectors?

Table of contents for Exosome Diagnostics Market Technologies:

1 Table of Contents 4

1.1 List of Tables 6

1.2 List of Figures 7

2 Exosomes in Healthcare 8

2.1 Overview of Exosomes 8

2.2 Drug Delivery Systems 9

2.2.1 Modified Release Drug Delivery Systems 9

2.2.2 Targeted Drug Delivery Systems 10

2.2.3 Liposomes 12

2.2.4 Viruses 14

2.2.5 Exosomes 17

2.3 The Exosome Lifecycle 18

2.4 Exosomes in Biology 18

2.5 Exosomes in Medicine 19

2.5.1 Biomarkers 19

2.5.2 Vaccines 20

2.6 Exosomes as a Therapeutic Target 20

2.7 Exosomes as Drug Delivery Vehicles 21

2.8 Therapeutic Preparation of Exosomes 21

2.8.1 Isolation and Purification 22

2.8.2 Drug Loading 22

2.8.3 Characterization 23

2.8.4 Bioengineering 23

2.8.5 Biodistribution and In Vivo Studies 23

2.8.6 Advantages of Exosome Therapies 24

2.8.7 Disadvantages of Exosome Therapies 24

2.9 Exosomes in Therapeutic Research 25

2.9.1 Exosome Gene Therapies 25

2.9.2 Exosome in Stem Cell Therapy 26

2.10 Exosomes in Oncology 27

2.10.1 Immunotherapy 27

2.10.2 Gene Therapy 28

2.10.3 Drug Delivery 29

2.10.4 Biomarkers 30

2.11 Exosomes in CNS Disease 30

2.11.1 Tackling the Blood-Brain Barrier 30

2.11.2 Exosomes in CNS Drug Delivery 31

2.11.3 Gene Therapy 32

2.12 Exosomes in Other Diseases 33

2.12.1 Cardiovascular Disease 33

2.12.2 Metabolic Disease 33

3 Assessment of Pipeline Product Innovation 36

3.1 Overview 36

3.2 Exosome Pipeline by Stage of Development and Molecule Type 36

3.3 Pipeline by Molecular Target 37

3.4 Pipeline by Therapy Area and Indication 38

3.5 Pipeline Product Profiles 38

3.5.1 AB-126 - ArunA Biomedical Inc. 38

3.5.2 ALX-029 and ALX-102 - Alxerion Biotech 39

3.5.3 Biologics for Autism - Stem Cell Medicine Ltd 39

3.5.4 Biologic for Breast Cancer - Exovita Biosciences Inc. 39

3.5.5 Biologics for Idiopathic Pulmonary Fibrosis and Non-alcoholic Steatohepatitis - Regenasome Pty 39

3.5.6 Biologic for Lysosomal Storage Disorder - Exerkine 39

3.5.7 Biologics for Prostate Cancer - Cells for Cells 40

3.5.8 CAP-2003 - Capricor Therapeutics Inc. 40

3.5.9 CAP-1002 - Capricor Therapeutics Inc. 41

3.5.10 CIL-15001 and CIL-15002 - Ciloa 42

3.5.11 ExoPr0 - ReNeuron Group Plc 42

3.5.12 MVAX-001 - MolecuVax Inc. 43

3.5.13 Oligonucleotides to Activate miR124 for Acute Ischemic Stroke - Isfahan University of Medical Sciences 44

3.5.14 Oligonucleotides to Inhibit KRAS for Pancreatic Cancer - Codiak BioSciences Inc. 44

3.5.15 Proteins for Neurology and Proteins for CNS Disorders and Oligonucleotides for Neurology - Evox Therapeutics Ltd 44

3.5.16 TVC-201 and TVC-300 - Tavec Inc. 45

4 Assessment of Clinical Trial Landscape 48

4.1 Interventional Clinical Trials 48

4.1.1 Clinical Trials by Therapy Type 48

4.1.2 Clinical Trials by Therapy Area 49

4.1.3 Clinical Trials by Stage of Development 50

4.1.4 Clinical Trials by Start Date and Status 50

4.2 Observational Clinical Trials 51

4.2.1 Clinical Trials by Therapy Type 51

4.2.2 Clinical Trials by Therapy Area 51

4.2.3 Clinical Trials by Stage of Development 52

4.2.4 Clinical Trials by Start Date and Status 53

4.2.5 List of All Clinical Trials 54

5 Company Analysis and Positioning 67

5.1 Company Profiles 67

5.1.1 Capricor Therapeutics Inc. 67

5.1.2 Evox Therapeutics Ltd 72

5.1.3 ReNeuron Group Plc 73

5.1.4 Stem Cell Medicine Ltd 77

5.1.5 Tavec Inc. 78

5.1.6 Codiak Biosciences Inc. 80

Originally posted here:

Current research: 2020 Latest Report on Exosome Diagnostics Market Report Technologies, Analyze the Pipeline Landscape and Key Companies - WhaTech...

Five things you should know about psoriasis – Daily Herald

Red, scaly patches on your skin can be embarrassing, and you might do your best to hide them when youre out in public.

If you are living with these signs of psoriasis, however, you are far from alone. In the United States, about 8 million people have a form of psoriasis.

Psoriasis can cause significant discomfort, both physically and emotionally. It is more than just dry skin, and treating it is important to improve quality of life.

Read on to learn more about this condition, who is at risk, the complications and how it is treated and prevented.

Psoriasis is a hereditary skin condition that causes areas of the skin to shed rapidly. It can cause patches of raised skin or blisters on the scalp, elbows, knees, trunk or lower back. It is a chronic condition that can return multiple times. There are many kinds of psoriasis, with plaque psoriasis being the most common form.

People with a family history of psoriasis have a higher risk of developing it themselves. It can be triggered by stress or emotional disorders, or even by certain types of medication. Infections or skin injuries can also cause a flare-up.

A common side effect of psoriasis is psoriatic arthritis, which affects between 10 and 30 percent of people with the condition. Psoriatic arthritis causes inflammation in the joints and may damage joints permanently. People with psoriasis also have a higher chance of developing diabetes, heart disease and other serious conditions.

Various treatments can improve psoriasis symptoms. Topical treatments include steroid creams, vitamin A or vitamin D3 creams, and moisturizers. Medications are also available, though some are reserved for severe cases due to serious potential side effects. Ultraviolet light treatments can also reduce inflammation.

Treatment for your psoriasis can vary as you age because your body may react differently to medications and your skin can change over time, says Dan Bushnell, administrator at Gramercy Court Assisted Living. If you begin to experience new side effects, or if treatments dont work as well as they did in the past, be sure to talk to your doctor about other options.

Psoriasis is hereditary, and there is no way to prevent a person from developing the condition at some point. However, avoiding triggers like stress, sunburns and infections can keep flare-ups at bay. Caring for your skin can keep the condition under control. Use creams, lotions and humidifiers to keep your skin moist. Watch out for medications that increase your risk for a flare-up.

Psoriasis can have a major impact on your quality of life, especially if you are dealing with a severe case. While this condition cant be cured, there are treatments to improve symptoms and reduce flare-ups. If you are experiencing psoriasis symptoms, work with your physician to find the right treatment to keep it from running your life.

Dr. Amy Osmond Cook is a health care technology consultant and VP of marketing at Simplus, a platinum Salesforce partner.

More here:

Five things you should know about psoriasis - Daily Herald

AbbVie’s Skyrizi hangs Novartis’ Cosentyx out to dry in head-to-head psoriasis study – Endpoints News

Skyrizi, a key drug in AbbVies post-Humira future, has added another feather to its cap.

On Tuesday, the IL-23 inhibitor emerged superior in a head-to-head327-patient trial against Novartis dominant Cosentyx in patients with moderate-to-severe plaque psoriasis.

Data showed Skyrizi induced significantly higher rates of skin clearance compared to Cosentyx, meeting the primary goal of superiority with at least a 90% improvement from baseline in the Psoriasis Area and Severity Index (PASI 90) at week 52. Overall, 87% of Skyrizi-treated patients hit PASI 90, versus 57% of Cosentyx-treated patients at the one year mark.

The other main goal of non-inferiority at week 16 74% of Skyrizi patients achieved PASI 90 compared to 66% of Cosentyx patients was also met. Skyrizi also eclipsed Cosentyx on all secondary endpoints, including PASI 100, and PASI 75.

In the fall of 2017, Skyrizi was evaluated against J&Js Stelara and its own Humira in a psoriasis study and emerged victorious, handsomely outpacing the rival drugs in clearing psoriasis.

These head-to-head studies are key to establishing Skyrizis position in a crowded market, which includes Humira, Novartis anti-IL17 Cosentyx, J&Js anti-IL23 Tremfya, anti-IL12/23 Stelara, as well as Lillys anti-IL17 Taltz.

Skyrizi is not the first pure IL-23 inhibitor to be approved Tremfya was approved in 2017 and Ilumya in 2018. But the AbbVie drug has a dosing advantage over Tremfya it is administered every 12 weeks, versus once every two months for Tremfya, SVB Leerinks Geoffrey Porges said on Wednesday, noting that other psoriasis biologics in addition to the oral Otezla generated a combined $11.1 billion in 2018 sales.

This does not include sales of anti-TNFs in psoriasis, which should decrease as patients move to these new, more efficacious therapies. These products also all achieved $500 million $1 billion in the second year of launch, which is likely to also be achieved by Skyrizi, SVB Leerinks Geoffrey Porges wrote in a note last year.

Overall biologics are still used in only 30% of the moderate to severe psoriasis population, (per JNJ in 2017), and AbbVies Skyrizi should benefit from both best-in-category efficacy (i.e. market share gains) and the continued rapid market expansion.

Skyrizi was approved in April 2019. AbbVie paid Boehringer Ingelheim $595 million upfront to license rights to the drug, known chemically as risankizumab, in early 2016.Evaluate has pegged Skyrizi as the number 3 blockbuster on its list of heavyweight drugs launched in 2019, estimating the drug could earn more than $2 billion in 2024 a far cry from AbbVies homegrown estimate of $4 billion to $5 billion in peak sales. Porges has forecast adjusted peak annual sales of $3 billion.

Last August, Lillys Taltz beat J&Js Tremfya in a head-to-head psoriasis study. In 2018, J&J ran its own head-to-head psoriasis trial against Cosentyx and came out with data that showed Tremfya superseded Novartis dominant rival.

Social image: AbbVie

Continue reading here:

AbbVie's Skyrizi hangs Novartis' Cosentyx out to dry in head-to-head psoriasis study - Endpoints News